Target
vascular endothelial growth factor receptor-2
2 abstracts
Abstract
Camrelizumab plus apatinib for advanced renal cell carcinoma patients after first-line tyrosine kinase inhibitor treatment failure: A multicenter phase II trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Imaging, Nuclear Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Department of General Internal Medicine,
Abstract
Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).Org: Department of Thoraci surgery, National Cancer Center Hospital East, Kashiwa, Japan, Division of Thoracic and Thyroid Surgery, Tokyo Medical University, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,